A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects

Clinical Drug Investigation

Volumn 36, Issue 2, 2016, Pages 119-126

  Li, Jianguo ^a   Learoyd, Maria ^a   Qiu, Furong ^b   Zhu, LeiLei ^b   Edeki, Timi ^a  

^a ASTRAZENECA   (United Kingdom)

^b Shuguang Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AVIBACTAM; BILIRUBIN; CEFTAZIDIME; PLACEBO; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; YOUNG ADULT;

EID: 84957426156     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-015-0347-x     Document Type: Article

References (31)

1. Liu YM, Chen YS, Toh HS, Huang CC, Lee YL, Ho CM, et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia–Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012;40(Suppl):S11–7.
2. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia–Pacific region: 2009–2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012;40(Suppl):S37–43.
3. World Health Organization. Antimicrobial resistance global report on surveillance. 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 4 Sept 2015.
4. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40:277–83.
5. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86:250–9.
6. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707.
7. Magiorakos AP, Suetens C, Monnet DL, Gagliotti C, Heuer OE. The rise of carbapenem resistance in Europe: just the tip of the iceberg? Antimicrob Resist Infect Control. 2013;2:6.
8. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.
9. Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: types, epidemiology and treatment. Saudi J Biol Sci. 2015;22:90–101.
10. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J Antimicrob Chemother. 2008;62:1053–6.
11. Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, et al. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother. 2009;64:326–9.
12. Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, et al. Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrob Agents Chemother. 2011;55:2434–7.
13. Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39:86–9.
14. Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, et al. In vitro antibacterial activity of the ceftazidime–avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56:1606–8.
15. Miossec C, Claudon M, Levasseur P, Black MT. The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β-lactamase in Enterobacter cloacae. Infect Drug Resist. 2013;6:235–40.
16. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind. Phase II trial. J Antimicrob Chemother. 2013;68:1183–92.
17. Vazquez JA, González Patzán LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime–avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28:1921–31.
18. Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig. 2015;35:307–17.
19. Wockhardt UK Ltd. Ceftazidime 1 g Powder for solution for injection. Summary of product characteristics. 2014. https://www.medicines.org.uk/emc/medicine/21129. Accessed 1 Jul 2015.
20. Mazuski JE, Gasink L, Armstrong J, Broadhurst H, Stone G, Rank D, et al. Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection—results from a Phase III program. In: 25th European Congress of Clinical Microbiology and Infectious Diseases 2015; abs 1713.
21. Carmeli Y, Armstrong J, Laud P, Newell P, Stone G, Wardman A, Gasink L. Efficacy and safety of ceftazidime–avibactam versus best available therapy in the treatment of ceftazidime-resistant infections—results from a Phase III study. In: European Congress of Clinical Microbiology and Infectious Diseases 2015; abs LBEV0061b.
22. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, et al. Ceftazidime–avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73:159–77.
23. Das S, Li J, Armstrong J, Learoyd M, Edeki T. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam and metronidazole in healthy subjects. Pharmacol Res Perspect. 2015;3(5):1–15.
24. Tominaga N, Edeki T, Li J, Learoyd M, Bouw MR, Das S. Phase I study assessing the safety, tolerability and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother. 2015;21:551–8.
25. Sillén H, Mitchell R, Sleigh R, Mainwaring G, Catton K, Houghton R, et al. Determination of avibactam and ceftazidime in human plasma samples by LC–MS. Bioanalysis. 2015;7:1423–34.
26. Baietto L, Corcione S, Pacini G, Perri GD, D’Avolio A, De Rosa FG. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab. 2014;15:581–98.
27. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417–23.
28. Edeki T, Armstrong J, Li J. Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers. In: 53rd international conference on antimicrobial agents and chemotherapy; abs A1019.
29. Vishwanathan K, Mair S, Gupta A, Atherton J, Clarkson-Jones J, Edeki T, et al. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug–drug interaction potential. Drug Metab Dispos. 2014;42:932–42.
30. Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther. 2015;37:877–86.
31. Sommers DK, Walters L, Van Wyk M, Harding SM, Paton AM, Ayrton J. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983;23:892–6.